Cheng Su,1,* Cai Li,2,* Xinyi Hu,3,* Jing Wang,1,* Linlin Liu,4,* Xianfeng Zhang,4 Yeqing Tong4 

1School of Public Health, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 2Infectious Disease Prevention and Control Center, Wuhan Center for Disease Control and Prevention, Wuhan, Hubei, People’s Republic of China; 3Global Study Institute, University of Geneva, Geneva, 1205, Switzerland; 4Infectious Disease Prevention and Control Center, Hubei Center for Disease Control and Prevention, Wuhan, Hubei, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Yeqing Tong; Xianfeng Zhang, Email t_yeqing@163.com; 63382251@qq.com

Abstract: Angiotensin-converting enzyme 2 (ACE2) is an important regulator of the Renin-Angiotensin System (RAS). Additionally, it has been identified as a functional receptor for the Coronavirus. Research indicates that ACE2 plays a role in the regulation of cardiovascular systems by modulating blood pressure and electrolyte balance. Its role in pulmonary diseases has also garnered significant attention due to the widespread prevalence of Coronavirus. There is solid evidence linking ACE2 to other pulmonary diseases, including chronic obstructive pulmonary disease, acute respiratory distress syndrome, allergic asthma, among others. However, the exact pathological and physiological mechanisms of ACE2 in these diseases remain elusive. Our research aims to review and explore the latest advancements in ACE2-related studies in pulmonary diseases. These findings have the potential to open new avenues for utilizing ACE2 as a potential biomarker for early diagnosis and monitoring of pulmonary diseases.

Keywords: ACE2, lung diseases, ARDS, Lung Cancer, COPD